
**ELISA data on clinical samples**

For SLIT-2, the majority of the benign (48/52), Ta (41/46), T1 (34/36) and T2+ (28/29) samples were positive. Also, theT2+ samples showed a statistical difference compared to Benign and Ta groups (p-value<0.05). For SPARC, very few benign (4/20), Ta (2/21) and T1 (4/20) samples were positive compared to the T2+ positive samples (9/21). Furthermore, the T2+ samples showed a statistical difference compared to the other groups (\*p-value<0.05). (**Figs A, B**)

****

**Figure A. ELISA data in urine samples (Benign controls and BC cases Ta, T1, T2+) for SLIT-2. (\*p≤0.05)**

**Figure B. ELISA data in urine samples (Benign controls and BC cases Ta, T1, T2+) for SPARC. (\*p≤0.05)**